Design, synthesis, and biological evaluation of new 4-thiazolidinone derivatives substituted with benzimidazole ring as potential chemotherapeutic agents

Medicinal Chemistry Research

Volumn 22, Issue 2, 2013, Pages 707-725

  Masoud, Georgina N ^a   Youssef, Amal M ^a   Abdel Khalek, Magdy M ^a   Abdel Wahab, Abeer E ^b   Labouta, Ibrahim M ^a   Hazzaa, Aly A B ^a  

^a Alexandria University Faculty of Pharmacy   (Egypt)

^b Universities and Research Institutes District   (Egypt)

Author keywords

Antiviral activity; Breast cancer; NAT1; Thiazolidinones and benzimidazoles

Indexed keywords

1 [(1H BENZO[DEXTRO]IMIDAZOL 2 YL)METHYL] 3 (4 CHLOROPHENYL)THIOUREA; 1 [(1H BENZO[DEXTRO]IMIDAZOL 2 YL)METHYL] 3 (4 METHYL PHENYL)THIOUREA; 1 [(1H BENZO[DEXTRO]IMIDAZOL 2 YL)METHYL] 3 PHENYL THIOUREA; 3 [((1H BENZO[DEXTRO]IMIDAZOL 2 YL)LMETHYL) 4 OXO 2 THIOXOTHIAZOLIDIN 5 YLIDENE]INDOLIN 2 ONE; 3 [(1H BENZO[DEXTRO]IMIDAZOL 2 YL)METHYL] 2 (4 CHLOROPHENYLIMINO)THIAZOLIDIN 4 ONE; 3 [(1H BENZO[DEXTRO]IMIDAZOL 2 YL)METHYL] 2 (4 METHYL PHENYLIMINO)THIAZOLIDIN 4 ONE; 3 [(1H BENZO[DEXTRO]IMIDAZOL 2 YL)METHYL] 2 (PHENYLIMINO)THIAZOLIDIN 4 ONE; 3 [(1H BENZO[DEXTRO]IMIDAZOL 2 YL)METHYL] 2 THIOXOTHIAZOLIDIN 4 ONE; 3 [(1H BENZO[DEXTRO]IMIDAZOL 2 YL)METHYL] 5 (2 CHLOROBENZYLIDENE) 2 (PHENYLIMINO)THIAZOLIDIN 4 ONE; 3 [(1H BENZO[DEXTRO]IMIDAZOL 2 YL)METHYL] 5 (2 CHLOROBENZYLIDENE) 2 THIOXOTHIAZOLIDIN 4 ONE; 3 [(1H BENZO[DEXTRO]IMIDAZOL 2 YL)METHYL] 5 (2,4 DIMETHOXYBENZYLIDENE) 2 THIOXOTHIAZOLIDIN 4 ONE; 3 [(1H BENZO[DEXTRO]IMIDAZOL 2 YL)METHYL] 5 (2,5 DIMETHOXYBENZYLIDENE) 2 THIOXOTHIAZOLIDIN 4 ONE; 3 [(1H BENZO[DEXTRO]IMIDAZOL 2 YL)METHYL] 5 (3 PHENYL ALLYLIDENE) 2 THIOXOTHIAZOLIDIN 4 ONE; 3 [(1H BENZO[DEXTRO]IMIDAZOL 2 YL)METHYL] 5 (4 CHLOROBENZYLIDENE) 2 (PHENYLIMINO)THIAZOLIDIN 4 ONE; 3 [(1H BENZO[DEXTRO]IMIDAZOL 2 YL)METHYL] 5 (4 CHLOROBENZYLIDENE) 2 THIOXOTHIAZOLIDIN 4 ONE; 3 [(1H BENZO[DEXTRO]IMIDAZOL 2 YL)METHYL] 5 (4 DIMETHYL AMINOBENZYLIDENE) 2 THIOXOTHIAZOLIDIN 4 ONE; 3 [(1H BENZO[DEXTRO]IMIDAZOL 2 YL)METHYL] 5 (4 METHOXYBENZYLIDENE) 2 THIOXOTHIAZOLIDIN 4 ONE; 3 [(1H BENZO[DEXTRO]IMIDAZOL 2 YL)METHYL] 5 (4 NITROBENZYLIDENE) 2 (PHENYLIMINO)THIAZOLIDIN 4 ONE; 3 [(1H BENZO[DEXTRO]IMIDAZOL 2 YL)METHYL] 5 (4 NITROBENZYLIDENE) 2 THIOXOTHIAZOLIDIN 4 ONE; 3 [(1H BENZO[DEXTRO]IMIDAZOL 2 YL)METHYL] 5 (SULFACETAMIDO PHENYLAZO) 2 THIOXOTHIAZOLIDIN 4 ONE; 3 [(1H BENZO[DEXTRO]IMIDAZOL 2 YL)METHYL] 5 [(2SULFADIAZINYL)PHENYLAZO] 2 THIOXOTHIAZOLIDIN 4 ONE; 3 [(1H BENZO[DEXTRO]IMIDAZOL 2 YL)METHYL] 5 [(PYRIDIN 2 YL)METHYLENE] 2 THIOXOTHIAZOLIDIN 4 ONE; 3 [(1H BENZO[DEXTRO]IMIDAZOL 2 YL)METHYL] 5 [4 (CHLOROPHENYLAZO)] 2 THIOXOTHIAZOLIDIN 4 ONE; 3 [(1H BENZO[DEXTRO]IMIDAZOL 2 YL)METHYL] 5 BENZYLIDENE 2 (PHENYLIMINO)THIAZOLIDIN 4 ONE; 3 [(1H BENZO[DEXTRO]IMIDAZOL 2 YL)METHYL] 5 BENZYLIDENE 2 THIOXOTHIAZOLIDIN 4 ONE; 4 THIAZOLIDINONE DERIVATIVE; ANTINEOPLASTIC AGENT; BENZIMIDAZOLE DERIVATIVE; DOXORUBICIN; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; ANTIVIRAL ACTIVITY; ARTICLE; BREAST ADENOCARCINOMA; CELL STRAIN HCT116; CELL STRAIN HEPG2; CELL STRAIN MCF 7; COLON CARCINOMA; CONTROLLED STUDY; DRUG DESIGN; DRUG SYNTHESIS; HUMAN; HUMAN CELL; LIVER CELL CARCINOMA;

EID: 84873997765     PISSN: 10542523     EISSN: 15548120     Source Type: Journal    
DOI: 10.1007/s00044-012-0057-3     Document Type: Article

References (39)

1. Ayhan-Kilcigil G, Altanlar N (2003) Synthesis and antimicrobial activities of some new benzimidazole derivatives. Farmaco 58:1345-1350
2. Ayhan-Kilcigil G, Tuncbilek M, Altanlar N, Goker H (1999) Synthesis and antimicrobial activity of some new benzimidazole carboxylates and carboxamides. Farmaco 54:562-565
3. Barreiro E, Casas JS, Couce MD, Sanchez A, Sordo J, Varela JM, Vazquez-Lopez EM (2007) The influence of 5-substituents on the supramolecular structures of rhodanine derivatives. Cryst Growth Des 7:1964-1973
4. Borenfreund E, Puerner JA (1984) A simple quantitative procedure using monolayer cultures for cytotoxicity assays (HTD/NR-90). J Tissue Cult Meth 9:7-9
5. Brown FC (1961) 4-Thiazolidinones. Chem Rev 61:463-521
6. Bulic B, Pickhardt M, Khlistunova I, Biernat J, Mandelkow EM, Mandelkow E, Waldmann H (2007) Rhodanine-based tau aggregation inhibitors in cell models of tauopathy. Angew Chem Int Ed Engl 46:9215-9219
7. Cescon LA, Day AR (1962) Preparation of some benzimidazolylamino acids. Reactions of amino acids with o-phenylenediamines. J Org Chem 27:581-586
8. De Francesco R, Carfi A (2007) Advances in the development of new therapeutic agents targeting the NS3-4A serine protease or the NS5B RNA-dependent RNA polymerase of the hepatitis C virus. Adv Drug Deliv Rev 59:1242-1262
9. Edward BJ, Elizabeth W (2005) Cancer surpasses heart disease as leading cause of death for all but the very elderly. J Natl Cancer Inst 97:330-331
10. El-Awady MK, Ismail SM, El-Sagheer M, Sabour YA, Amr KS, Zaki EA (1999) Assay for hepatitis C virus in peripheral blood mononuclear cells enhances sensitivity of diagnosis and monitoring of HCV-associated hepatitis. Clin Chim Acta 283:1-14
11. El-Hawash SAM, Abdel Wahab AE, El-Demellawy MA (2006) Cyanoacetic acid hydrazones of 3-(and 4-)acetylpyridine and some derived ring systems as potential antitumor and anti-HCV agents. Arch Pharm Chem Life Sci 339:14-23
12. Evers DL, Komazin G, Ptak RG, Shin D, Emmer BT, Townsend LB, Drach JC (2004) Inhibition of human cytomegalovirus replication by benzimidazole nucleosides involves three distinct mechanisms. Antimicrob Agents Chemother 48:3918-3927
13. Fotakis G, Timbrell JA (2006) In vitro cytotoxicity assays: comparison of LDH, neutral red, MTT and protein assay in hepatoma cell lines following exposure to cadmium chloride. Toxicol Lett 160:171-177
14. Hirashima S, Suzuki T, Ishida T, Noji S, Yata S, Ando I, Komatsu M, Ikeda S, Hashimoto H (2006) Benzimidazole derivatives bearing substituted biphenyls as hepatitis C virus NS5B RNA-dependent RNA polymerase inhibitors: structure-activity relationship studies and identification of a potent and highly selective inhibitor JTK-109. J Med Chem 49:4721-4736
15. Holmberg B (1910) Preparation of rhodanins. J Prakt Chem 81:451-465
16. Hranjec M, Pavlovic G, Marjanovic M, Kralj M, Karminski-Zamola G (2010) Benzimidazole derivatives related to 2,3-acrylonitriles, benzimidazo[1,2-a] quinolines and fluorenes: synthesis, antitumor evaluation in vitro and crystal structure determination. Eur J Med Chem 45:2405-2417
17. http://info.cancerresearchuk.org
18. Husain MI, Srivastava GC, Dua PR (1982) 2-Alkyl-2-[4(3H)-oxo-2-(3,4,5- trimethoxyphenyl)-3-quinazolyl]ethanoic acids and their amides as anticonvulsant agents. Indian J Chem 21B:381-383
19. Kumar D, Jacob MR, Reynolds MB, Kerwin SM (2002) Synthesis and evaluation of anticancer benzoxazoles and benzimidazoles related to UK-1. Bioorg Med Chem 10:3997-4004
20. Lee CL, Sim MM (2000) Solid-phase combinatorial synthesis of 5-arylalkylidene rhodanine. Tetrahedron Lett 41:5729-5732
21. Li YF, Wang GF, He PL, Huang WG, Zhu FH, Gao HY, Tang W, Luo Y, Feng CL, Shi LP, Ren YD, Lu W, Zuo JP (2006) Synthesis and anti-hepatitis B virus activity of novel benzimidazole derivatives. J Med Chem 49:4790-4794
22. Middleton T, Lim HB, Montgomery D, Rockway T, Tang H, Cheng X, Lu L, Mo H, Kohlbrenner WE, Molla A, Kati WM (2004) Inhibition of human immunodeficiency virus type I integrase by naphthamidines and 2-aminobenzimidazoles. Antiviral Res 64:35-45
23. Molecular operating environment (MOE) 2009.10, Chemical Computing Group Inc., Montréal, Canada. http://www.chemcomp.com
24. Ohishi Y, Mukai T, Nagahara M, Yajima M, Kajikawa N, Miyahara K, Takano T (1990) Preparations of 5-alkylmethylidene-3-carboxymethylrhodanine derivatives and their aldose reductase inhibitory activity. Chem Pharm Bull 38:1911-1919
25. Pawar NS, Dalal DS, Shimpi SR, Mahulikar PP (2004) Studies of antimicrobial activity of N-alkyl and N-acyl 2-(4-thiazolyl)-1H-benzimidazoles. Eur J Pharm Sci 21:115-118
26. Powers JP, Piper DE, Li Y, Mayorga V, Anzola J, Chen JM, Jaen JC, Lee G, Liu J, Peterson MG, Tonn GR, Ye Q, Walker NP, Wang Z (2006) SAR and mode of action of novel non-nucleoside inhibitors of hepatitis C NS5b RNA polymerase. J Med Chem 49:1034-1046
27. Refaat HM (2010) Synthesis and anticancer activity of some novel 2-substituted benzimidazole derivatives. Eur J Med Chem 45:2949-2956
28. Rida SM, Labouta IM, Salama HM, Ghany YS, el-Ghazzaui E, Kader O (1986) Syntheses and in vitro antimicrobial evaluation of some benzimidazol-2- ylmethylthioureas, benzimidazol-2-ylacetylthiosemicarbazides and products of their condensation with monochloroacetic acid. Pharmazie 41:475-478
29. Russell AJ, Westwood IM, Crawford MH, Robinson J, Kawamura A, Redfield C, Laurieri N, Lowe ED, Davies SG, Sim E (2009) Selective small molecule inhibitors of the potential breast cancer marker, human arylamine N-acetyltransferase 1, and its murine homologue, mouse arylamine N-acetyltransferase 2. Bioorg Med Chem 17:905-918
30. Sinclair JC, Sandy J, Delgoda R, Sim E, Noble ME (2000) Structure of arylamine N-acetyltransferase reveals a catalytic triad. Nat Struct Biol 7:560-564
31. Sing WT, Lee CL, Yeo SL, Lim SP, Sim MM (2001) Arylalkylidene rhodanine with bulky and hydrophobic functional group as selective HCV NS3 protease inhibitor. Bioorg Med Chem Lett 11:91-94
32. Singh IP, Saxena AK, Shankar K (1986) Synthesis and anti-inflammatory activity of oxadiazoline thione hydrochlorides. Eur J Med Chem-Chim Ther 21:267-269
33. Skehan P, Storeng R, Scudiero D, Monks A, McMahon J, Vistica D, Warren JT, Bokesch H, Kenney S, Boyd MR (1990) New colorimetric cytotoxicity assay for anticancer-drug screening. J Natl Cancer Inst 82:1107-1112
34. Soliman R (1981) Synthesis of 4-substituted phenazone derivatives with possible hypoglycemic activity. Pharmazie 36:91 (Chem Abstr (1981) 95:62100)
35. St. Laurent DR, Gao Q, Wu D, Serrano-Wu MH (2004) Regioselective synthesis of 3- (heteroaryl)-iminothiazolidin-4-ones. Tetrahedron Lett 45:1907-1910
36. Strube RE (1959) N-(p-Acetylaminophenyl)rhodanine. Org Synth 39:1-2
37. Wakefield L, Robinson J, Long H, Ibbitt JC, Cooke S, Hurst HC, Sim E (2008) Arylamine N-acetyltransferase 1 expression in breast cancer cell lines: a potential marker in estrogen receptor-positive tumors. Genes Chromosome Canc 47:118-126
38. Weinshilboum R (2008) Pharmacogenomics of endocrine therapy in breast cancer. Adv Exp Med Biol 630:220-231
39. Zhu Y, Wang A, Liu MC, Zwart A, Lee RY, Gallagher A, Wang Y, Miller WR, Dixon JM, Clarke R (2006) Estrogen receptor alpha (ER) positive breast tumors and breast cancer cell lines share similarities in their transcriptome data structures. Int J Oncol 29:1581-1589